Small incision lenticule extraction (SMILE) with micromonovision vs LASIK micromonovision
Session Details
Session Title: Small Lenticule Extraction I
Session Date/Time: Sunday 15/09/2019 | 08:00-10:00
Paper Time: 09:36
Venue: Free Paper Forum: Podium 1
First Author: : A.Aguayo CANADA
Co Author(s): : C. Kranemann
Abstract Details
Purpose:
To determine the efficacy and safety of SMILE with micromonovision vs. Lasik Micromonovision (Presbyond)
Setting:
Refractive clinic
Methods:
Prospective cohort of patients underwent SMILE with micromonovision vs. Presbyond. All patients had pre- and postoperative topography/wavefront/cycloplegic refractions/endothelial cell count/tear osmolality and recording of any complications. All patients were tested for micromonovision tolerance preoperatively for up to 1.5 diopters. The spherical aberrations were modulated in the SMILE group by varying the lenticule diameter.
Results:
84 eyes of 42 patients were treated. 44 underwent SMILE micromonovision and 40 Prebyond (NS). The preoperative refraction ranged for -1.5 to -10.0 of sphere and -.5 to -2.5 of cylinder. Then mean age was 49.2 years. The micromonovision ranged from -.75 to -1.5 diopters.
At month 6 uncorrected distance visual acuity (UDVA) was a mean of 20/18 in both groups. UIDVA (intermediate) was 20/20 in both groups. UNDVA (near) was a mean of 20/23 for SMILE micromonovision and 20/20 for Presbyond (P<.1).
Tear osmolality was 306 in the SMILE group and 316 in the Presbyond group (P.1). Dry eye complaints were present in 4/22 SMILE patients and 9/20 Presbyond patients (P .3). The SMILE group required 4 touch ups versus 3 touch ups in the Presbyond group.
There were no complications in either group.
Conclusions:
Both SMILE with mciromonovision and Presbyond appeared to be effective in achieving presbyopia correction with slightly better uncorrected reading vision in the Presbyond and slightly less dry eye issues in the SMILE group. These trends will require larger and more long term study to determine their relevance.
Financial Disclosure:
None